Annals of Surgical Oncology最新文献

{"title":"Somatostatin Analogs for Preventing Postoperative Pancreatic Fistula: Past Evidence Reveals New Opportunities.","authors":"Kristin E Goodsell, Sardar Shahmir B Chauhan, Venu G Pillarisetty, Jonathan G Sham","doi":"10.1245/s10434-025-17660-8","DOIUrl":"10.1245/s10434-025-17660-8","url":null,"abstract":"<p><p>Postoperative pancreatic fistula (POPF) is the defining complication following pancreatectomy. The incidence of POPF after pancreatic resection remains high even at experienced centers, with associated patient morbidity, increased healthcare costs, and poorer oncologic outcomes. There is evidence that POPF is more frequent after distal pancreatectomy. On the basis of the premise that reduction in pancreatic exocrine secretion reduces the risk of fistula formation, somatostatin analogs (SSA) to prevent POPF and its sequelae have been studied for more than 30 years. However, evidence regarding their efficacy remains mixed. Early multicenter randomized control trials demonstrated a benefit of octreotide in reducing POPF, although subsequent single-center studies failed to confirm these results. Despite additional studies demonstrating a significant reduction in POPF with the use of newer SSAs including pasireotide and lanreotide, surgical practices in the use of somatostatin analogs in preventing POPF are highly variable. Herein, we review three decades of available data on SSA for POPF prophylaxis and highlight the need for pragmatic, focused, and data-driven design for future trials with modern agents.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7382-7392"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for and Oncologic Impact of Anastomotic Leakage After Sphincter-Preserving Proctectomy for Mid/Low Rectal Cancer: A Multi-institutional Cohort Study in Japan.","authors":"Kentaro Ochiai, Koya Hida, Tomohiro Yamaguchi, Meiki Fukuda, Tomonori Akagi, Takashi Akiyoshi, Ryosuke Okamura, Seiichiro Yamamoto, Takeshi Naitoh, Tsuyoshi Konishi","doi":"10.1245/s10434-025-17763-2","DOIUrl":"10.1245/s10434-025-17763-2","url":null,"abstract":"<p><strong>Background: </strong>Anastomotic leakage after sphincter-preserving proctectomy is a serious postoperative complication. It is unclear whether diverting ostomy prevents anastomotic leakage, and whether anastomotic leakage worsens long-term oncologic outcomes.</p><p><strong>Patients and methods: </strong>Data from patients with stage II-III mid/low rectal cancer who underwent sphincter-preserving proctectomy between January 2010 and December 2011 were retrospectively analyzed using a multicenter database from 69 institutions. Factors associated with anastomotic leakage and its influence on oncologic outcomes were evaluated.</p><p><strong>Results: </strong>A total of 922 patients were included. Anastomotic leakage was diagnosed in 125 patients (13.6%). Anastomotic leakage was associated with increased reoperations (29.6% vs. 1.0%, p < 0.0001), longer hospital stays (median 34 days vs. 15 days, p < 0.0001), and more frequent permanent ostomy (20.8% vs. 11.0%, p = 0.002). Multivariable analysis revealed that absence of diverting ostomy (odds ratio 2.46, 95% confidential interval 1.59-3.85, p = 0.0004) and male sex (odds ratio 2.54, 95% confidence interval 1.58-4.26, p = 0.001) were independently associated with an increased risk of anastomotic leakage. The risk reduction with diverting ostomy was observed in both sexes in interaction term analysis. Anastomotic leakage was associated with an increased risk of local recurrence in patients with pathologic stage III disease (hazard ratio 2.11, 95% confidence interval 1.08-4.14, p = 0.03) but was not associated with overall or recurrence-free survival.</p><p><strong>Conclusions: </strong>Absence of diverting ostomy and male sex were risk factors for anastomotic leakage, and anastomotic leakage was associated with increased local recurrence in patients with stage III disease. These findings support the practice of protective diversion after sphincter-preserving proctectomy in patients with mid/low rectal cancer.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7315-7325"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Intratumoral Lipopolysaccharide as a Novel Biomarker of the Tumor Microenvironment and Prognosis in Esophageal Squamous Cell Carcinoma.","authors":"Shintaro Uchida, Takehiko Yokobori, Kota Yanagisawa, Bilguun Erkhem-Ochir, Gendensuren Dorjkhorloo, Haruka Okami, Chika Katayama, Yuta Shibasaki, Nobuhiro Nakazawa, Chika Komine, Takuya Shiraishi, Takuhisa Okada, Katsuya Osone, Akiharu Kimura, Akihiko Sano, Makoto Sakai, Nobuo Sasaki, Ken Shirabe, Hiroshi Saeki","doi":"10.1245/s10434-025-17919-0","DOIUrl":"10.1245/s10434-025-17919-0","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"8062-8063"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hashimoto's Thyroiditis Shows Sex- and Age-Dependent Inverse Associations with Papillary Thyroid Carcinoma Progression: A Propensity Score-Matched Analysis of 6963 Surgical Cases.","authors":"Chi Ma, Jie Xu, Guibin Zheng, Lujia Liu, Xicheng Song, Haitao Zheng","doi":"10.1245/s10434-025-17842-4","DOIUrl":"10.1245/s10434-025-17842-4","url":null,"abstract":"<p><strong>Introduction: </strong>The coexistence of papillary thyroid carcinoma (PTC) and Hashimoto's thyroiditis (HT) presents a clinically significant yet controversial association in endocrine pathology. This study aimed to systematically evaluate the potential inverse associations between HT and PTC progression through comprehensive clinicopathological analysis.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 6963 surgical PTC patients treated at our tertiary referral center between 2009 and 2023. Using propensity score matching to control for baseline confounders, we performed Chi-square tests and logistic regression analyses adjusted for key pathological parameters.</p><p><strong>Results: </strong>Overall, 6963 patients were included in this study. Analysis revealed that male patients with PTC had a lower risk of concurrent HT (odds ratio [OR] 0.29, p < 0.001) and HT-positive patients were significantly younger than their HT-negative counterparts (p = 0.02). Propensity score-matched analysis demonstrated that HT served as a protective factor against lymph node metastasis (OR 0.802, p < 0.001), tumor capsular invasion (OR 0.86, p = 0.004), and BRAF V600E mutation (OR 0.579, p = 0.039). In subgroup analyses, the association between HT and PTC was exclusively observed in female patients, with its correlation with reduced lymph node metastasis primarily seen in the <55 years age group, while the inverse association with capsular invasion was more pronounced in the ≥55 years age group.</p><p><strong>Conclusion: </strong>These findings suggest potential sex- and age-dependent associations between HT and less aggressive PTC characteristics, with the strongest correlations observed for reduced metastatic tendency in younger women and decreased local invasion in older patients. The observed BRAF mutation modulation suggests potential immune-mediated tumor microenvironment alterations warranting further molecular investigation.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7498-7504"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic Outcomes of Intraoperative Autologous Blood Transfusion for Major Oncologic Resection.","authors":"Chelsea Powell, Courtney Day, Vidit Sharma, Camille van Buskirk, Matthew A Warner, Elizabeth B Habermann, Matthew Houdek, Timucin Taner, Julie Heimbach, Cornelius Thiels","doi":"10.1245/s10434-025-18024-y","DOIUrl":"10.1245/s10434-025-18024-y","url":null,"abstract":"<p><strong>Background: </strong>Intraoperative autologous blood transfusion (IABT) is contraindicated during oncologic resection owing to concern for metastasis. However, there is a paucity of data to substantiate this claim, and the true risk of IABT in patients with cancer remains unknown.</p><p><strong>Patients and methods: </strong>We identified patients who underwent oncologic resection with IABT during 2010-2021 at our institution. The primary outcome was early metastasis. A subgroup analysis of patients who underwent liver transplants for malignancy was conducted using inverse probability of treatment weighting to compare survival between those who received autologous and allogeneic transfusions.</p><p><strong>Results: </strong>Of 444 patients, the most common diagnoses were hepatocellular carcinoma (235, 52.9%), cholangiocarcinoma (68, 15.3%), and renal cell carcinoma (18, 4.1%). The median volume of autologous blood transfused was 661 mL (interquartile range (IQR) 337-1491 mL). A total of 7 patients (1.6%) experienced distant recurrence within 90 days, and 35 (7.9%) within 1 year. Of the seven patients with early distant recurrence, only one had metastasis not attributable to preoperative factors. In a subgroup analysis of patients undergoing liver transplant for malignancy, 299 patients who received IABT were compared with 107 patients who received allogeneic transfusion. After adjusting for cancer type, age, sex, estimated blood loss, model for end-stage liver disease (MELD) score, stage, and allograft type, IABT was not associated with overall survival (OS) [adjusted hazard ratio (AHR) 1.30 (95% confidence interval (CI) 0.82-2.03), p = 0.241] or recurrence-free survival (RFS) [AHR 1.15 (95% CI 0.77-1.73), p = 0.498].</p><p><strong>Conclusions: </strong>IABT does not appear to be associated with early recurrence in patients undergoing oncologic resection. IABT should be investigated as a possible alternative to massive transfusion of allogeneic blood during oncologic resection.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7644-7651"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-Based Differences in Medullary Thyroid Cancer Survival: A Matched Analysis of 4602 Patients.","authors":"Nathan Gabriel Sattah, Vincent M D'Anniballe, Samantha M Thomas, Alberto J Monreal, Randall Paul Scheri, Hadiza Shu'aib Kazaure","doi":"10.1245/s10434-025-18067-1","DOIUrl":"10.1245/s10434-025-18067-1","url":null,"abstract":"<p><strong>Background: </strong>Whereas medullary thyroid cancer (MTC) is more common in female patients, studies have indicated that MTC is more aggressive in males. It is unknown whether sex-based differences in MTC outcomes are due to inherent tumor behavior or factors such as care characteristics.</p><p><strong>Methods: </strong>Patients with MTC stages I to IV were identified using the National Cancer Database (2004-2020). Male patients were matched one-to-one with females based on pathologic staging. Overall survival (OS) was estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate the association of biologic sex with OS.</p><p><strong>Results: </strong>The study matched 4062 patients (2031 females and 2031 males). The median age was 55 years (interquartile range, 43-66 years). Age, race, comorbidity score, and care characteristics such as time to diagnosis and surgery type did not differ by sex (all p > 0.05). Pathologic stage was primarily stage IVA (35.5%), followed by stages I (24.7%) and III (18.9%). The unadjusted 10-year OS for the female patients was 81.1% (95% confidence interval [CI], 78.7-83.2%) versus 69.6% (95% CI 66.8-72.3%) for the male patients (p < 0.001, log-rank). Survival for the male patients with stages II, III, and IVA disease was significantly worse (all p < 0.05). After multivariable adjustment, the male patients showed an 81% higher mortality risk than the female patients (hazard ratio [HR], 1.81, 95% CI 1.50-2.20; p < 0.001).</p><p><strong>Conclusions: </strong>Despite patient-matching and adjustment for several factors, the male patients with MTC demonstrate worse survival than the matched female patients. These findings indicate that MTC behavior differs by sex.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7505-7515"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and Validation of an Impaction-Nozzle Nebuliser for Enhanced Distribution Uniformity in Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Applications.","authors":"Yaroslaw Sautkin, Hans Schoenfelder, Marc André Reymond","doi":"10.1245/s10434-025-17602-4","DOIUrl":"10.1245/s10434-025-17602-4","url":null,"abstract":"<p><strong>Introduction: </strong>This study introduces and validates the CapnoTip^®, an impaction-based pressurised intraperitoneal aerosol chemotherapy (PIPAC) nebuliser designed to enhance intraperitoneal drug delivery and achieve greater homogeneity to improve treatment outcomes for peritoneal metastasis.</p><p><strong>Methods: </strong>CapnoTip^® was characterised through physical experiments evaluating aerosol granulometry, spray patterns, and aerosolisation angle. Pharmacological efficacy was assessed by using the ex vivo enhanced inverted bovine urinary bladder (eIBUB) model to measure intraperitoneal cisplatin concentration and distribution homogeneity and compare the result to that of the clinical reference nebuliser, CapnoPen^®.</p><p><strong>Results: </strong>Aerosol granulometry using distilled water measured 26.1 µm (confidence interval [CI] 13.6-59.6) for CapnoTip^® and 27.9 µm (CI 14.8-59.4) for CapnoPen^®. When using 10 cSt silicone oil, droplet sizes were 56.0 µm (CI 18.4-245.0) for CapnoTip^® versus 33.8 µm (CI 14.3-66.5) for CapnoPen^®. The aerosolisation angle was broader with the CapnoTip^® compared with the CapnoPen^® (155.3° vs. 67.1°). CapnoTip^® achieved a uniform intraperitoneal drug distribution, with no significant cisplatin gradient along the aerosolisation axis (p > 0.05). In contrast, CapnoPen^® showed marked concentration gradients between the test organ's top vs. bottom and middle vs. bottom regions (p < 0.001). A significantly higher mean intraperitoneal cisplatin concentration was achieved with the CapnoTip^® (56.8 ± 25.1 ng/mg) compared with the CapnoPen^® (39.2 ± 31.1 ng/mg; p = 0.026).</p><p><strong>Conclusions: </strong>The CapnoTip^® impaction-nozzle nebuliser for PIPAC is technically and pharmacologically equivalent to the CE-approved CapnoPen^®, while offering superior intraperitoneal drug delivery and distribution homogeneity.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7981-7989"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.","authors":"Natasha Venugopal, Jorge Raul Vazquez-Urrutia, Junjia Zhu, Asato Hashinokuchi, Shinkichi Takamori, Takefumi Komiya","doi":"10.1245/s10434-025-17766-z","DOIUrl":"10.1245/s10434-025-17766-z","url":null,"abstract":"<p><strong>Background: </strong>Currently, atezolizumab and pembrolizumab are standard management for curatively resected stage II-III non-small cell lung cancer (NSCLC) owing to prior studies showing that they improve disease-free survival. However, these studies excluded the planned use of adjuvant radiation therapy. Survival benefit of adding immune checkpoint inhibitor (ICI) in patients treated with adjuvant chemoradiation (CT+RT) has not been fully assessed.</p><p><strong>Methods: </strong>Using National Cancer Database (NCDB), we identified and, based on therapy received, stratified 4,934 cases involving patients undergoing complete resection with pathologic stage II-IIIB NSCLC who survived at least 1 month without neoadjuvant CT or RT and subsequently received adjuvant chemotherapy. Kaplan-Meier methods and multi-variable Cox regression models were used for survival analysis. Propensity score matching was performed to compare adjuvant CT+RT+ICI vs. CT+RT. A p-value of <0.05 was considered statistically significant.</p><p><strong>Results: </strong>The addition of ICI to adjuvant CT improved overall survival (OS) (2-year OS 90.1% vs. 86%, univariate and multivariate hazard ratios [HRs] 0.72 and 0.66, p = 0.0024 and 0.0003, respectively). However, no OS benefit was seen in those who received adjuvant CT+RT (2-year OS 77.8% vs. 76.1%, univariate and multivariate HRs 0.83 and 0.85, p = 0.3677 and 0.4369, respectively). Propensity score matching analysis showed similar results (2-year OS 77.8% vs. 79.6%, univariate and multivariate HRs 0.91 and 0.87, p = 0.7143 and 0.5868, respectively).</p><p><strong>Conclusions: </strong>Our retrospective real-world analysis suggests that adjuvant ICIs do not improve survival outcome when combined with adjuvant CT+RT. This result mirrors recent negative trials studying ICI+CT+RT in unresectable stage III NSCLC and limited-stage SCLC. Further investigations are warranted.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7883-7890"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of ACVR1 in Cancer-Associated Fibroblasts Suppresses Colorectal Cancer Cell Growth.","authors":"Shinya Kato, Norikatsu Miyoshi, Shiki Fujino, Masafumi Horie, Shinichi Yachida, Mitsunobu Takeda, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Mamoru Uemura, Hirofumi Yamamoto, Masayoshi Yasui, Masayuki Ohue, Yuichiro Doki, Hidetoshi Eguchi","doi":"10.1245/s10434-025-17765-0","DOIUrl":"10.1245/s10434-025-17765-0","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third most common malignancy worldwide and a leading cause of cancer-related mortality. Stromal signatures in CRC are correlated with poor prognosis and resistance to chemotherapy, affecting tumor progression and relapse. Although single-cell analyses have identified subpopulations of cancer-associated fibroblasts (CAFs), effective molecular targeted therapies against CAFs are lacking.</p><p><strong>Materials and methods: </strong>We employed organoid culture methods, focusing on two-dimensional organoids (2DOs) to mimic CRC histology. Using single-cell analysis, we investigated cancer-fibroblast crosstalk, with emphasis on activin receptor type I (ACVR1) in fibroblasts and bone morphogenetic protein 7 (BMP7) in cancer cells as potential therapeutic targets. The correlation between high ACVR1 and BMP7 expression levels and the prognosis of patients with stage II cancer was evaluated.</p><p><strong>Results: </strong>The 2DO mouse xenograft model replicated the characteristics of the fibroblast subpopulations present in human CRC tumors. Single-cell RNA sequencing identified fibroblast clusters, with the BMP7-ACVR1 axis emerging as a potential therapeutic target. High BMP7 and ACVR1 expression was significantly correlated with poor disease-free survival and overall survival in stage II CRC. Administration of an ACVR1 inhibitor during the coculture of 2DOs and mouse stromal cells inhibited tumor growth.</p><p><strong>Conclusions: </strong>ACVR1 is a promising therapeutic target that inhibits CAF proliferation. High BMP7 and ACVR1 expression is a significant prognostic factor in stage II CRC.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7333-7343"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Vascular Pancreatic Surgery Worldwide: A Call to Strengthen Rescue and Standardize Care.","authors":"Camila Hidalgo Salinas, Pascale Tinguely, Dimitri A Raptis, Giuseppe Kito Fusai","doi":"10.1245/s10434-025-18134-7","DOIUrl":"10.1245/s10434-025-18134-7","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7461-7462"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}